Prognostic value of level of brain natriuretic peptide in patients with acute coronary syndrome without symptoms of heart failure
Year: 2017, volume 13 Issue: №1 Pages: 041-046
Heading: Internal Diseases Article type: Original article
Authors: Furman N.V., Puchinyan N.F., Dolotovskaya P.V., Dovgalevsky la.P., Panina A.V.
Organization: Saratov Institute of Cardiology, Russia
Heading: Internal Diseases Article type: Original article
Authors: Furman N.V., Puchinyan N.F., Dolotovskaya P.V., Dovgalevsky la.P., Panina A.V.
Organization: Saratov Institute of Cardiology, Russia
Summary:
Purpose of the study: to evaluate the prognostic value of brain natriuretic peptide (BNP) as a predictor of cardiovascular events in patients with acute coronary syndrome (ACS) within one year after hospitalization. Material and Methods. The study included 201 patients, including 150 men and 51 women, who were treated in the emergency department of cardiology with ACS including 96 patients without symptoms of CHF and/or AHF. Results. All patients were divided into groups depending on the presence signs of heart failure of CHF and/or AHF at the time of admission: patients with no signs of heart failure were divided into 2 groups: those with BNP levels >101 pg/mL (group 1; n=37) and <100 pg/mL (group 2; n=59); the third group consisted of patients with symptomatic HF (n=105). In patients without clinical signs of CHF and/or AHF with elevated level of the BNP at the time of hospitalization was observed significantly increased risk of unstable angina during the year compared to patients with normal levels (OR 2.83 [95% Cl: 1.1—7.24], p=0.04). In patients without clinical signs of CHF and/or AHF with elevated BNP levels at the time of hospitalization compared to patients with AHF and/or CHF, had no statistically significant differences in the long-term prognosis. Conclusion. Patients with ACS in the absence of CHF and/or AHF but with elevated levels of BNP at admission should be attributed to the group of high risk for cardiovascular complications. Increasing the level of BNP in ACS patients at admission has an adverse value for long-term outcome and can be used as an additional risk marker.
Bibliography:
1. Provotorov VM, Shevchenko II. Long-term trends and predictors of the clinical course and outcome in acute coronary syndrome. Russ J Cardiol 2012, 5 (97): 40-45
2. Bedetti G, Gargani L, Sicari R, et al. Comparison of prognostic value of echo graphic risk score with the Thrombolysis in Myocardial Infarction (TIMI) and Global Registry in Acute Coronary Events (GRACE) risk scores in acute coronary syndrome. Am J Cardiol 2010; 106(12): 1709-16
3. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes: A Report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines Circulation. 2014; 000:000-000. http://circ.ahajournals.org/content/early/2014/09/22/ CIR.0000000000000134.citation
4. Scirica BM. Acute Coronary Syndrome. Emerging Tools for Diagnosis and Risk Assessment. JAm Coll Cardiol 2010; 55: 1403-1415
5. McCann CJ, Glover BM, Menown IB, et al. Prognostic Value of a Multimarker Approach for Patients Presenting to Hospital With Acute Chest Pain. Am J Cardiol 2009; 103: 22-28
6. Eggers KM, Kempf T, Venge P, et al. Improving long-term risk prediction in patients with acute chest pain: The Global Registry of Acute Coronary Events (GRACE) risk score is enhanced by selected non-necrosis biomarkers. American Heart Journal 2010; 160:88-94
7. Kopitsa NP, Titarenko NV, Belaya NV, Peteneva LL. Prognostic value of brain natriuretic peptide in patients with acute coronary syndrome. International Medical Journal. 2011; 1: 54-57
8. Corcoran D, Grant Р, Berry С. Risk stratification in non-ST elevation acute coronary syndromes: Risk scores, biomarkers and clinical judgment. IJC Heart & Vasculature 2015; 8:131 -137
9. Bassan F, Bassan R, Esporcatte R. Very Long-Term Prognostic Role of Admission BNP in Non-ST Segment Elevation Acute Coronary Syndrome. Arq Bras Cardiol 2016; 106 (3): 218-225
10. Kang Q, Wan Z, Huang Z. N-terminal probrain natriuretic peptide in patients with acute coronary syndrome. Int J Clin Pharmacol Ther 2016 Nov 23. [Epub ahead of print]
11. Barbarash OL, Usol'tseva EN. Location of brain natriuretic peptide in predicting of the course of acute coronary syndrome. Pathology of the circulatory and cardiac surgery 2010; 4: 74-78
12. Vasyuk YuA, Kulikov KG, Krikunova OV, et al. Serum brain natriuretic peptide and its role in acute coronary syndrome with different types of mitochondrial dysfunction. Clinical Medicine (Klinicheskaya Meditsina) 2013; 91 (3): 25-27
13. Talwar S, Squire IB, Downie PF, et al. Plasma N terminal pro-brain natriuretic peptide and cardiotroponin I are raised in unstable angina. Heart 2000; 84: 421-424
14. Lemos JA de, Morrow DA. Brain natriuretic peptide measurement in acute coronary syndromes: ready for clinical application? Circulation 2002; 106: 2868-2870
15. Volpe M, Rubattu S, Burnett Jr J. Natriuretic peptides in cardiovascular diseases: current use and perspectives. Eur Heart J 2014; 35: 419-425
16. Dokainish H, Zoghbi WA, Al-Bakshy FA, et al. Optimal noninvasive assessment of left ventricular filling pressures. A comparison of tissue doppler echocardiography and B-type natriuretic peptide in patients with pulmonary artery catheters. Circulation 2004; 109 (20): 2432-2439
17. Morrow DA, Lemos JA de, Sabatine MS, et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina non-ST-elevation myocardial infarction. B-type natriuretic peptide and prognosis in TACTICS-TIMI 18. JAm Coll Cardiol 2003; 41: 1264-1272
18. Talwar S, Squire IB, Downie PF, et al. Profile of plasma N-terminal proBNP following acute myocardial infarction; correlation with left ventricular systolic dysfunction. Eur Heart J 2000; 21: 1514-21
19. Galvani M, Ferrini D, Ottani F. Natriuretic peptides for risk stratification of patients with acute coronary syndromes. Eur J Heart Failure 2004: 6; 327-333
20. Luchner A, Hengstenberg C, Lbwel H, et al. Effect of compensated renal dysfunction on approved heart failure markers: direct comparison of brain natriuretic peptide (BNP) and N-terminal pro-BNP Hypertension. 2005; 46 (1): 118-123
21. Wang TJ, Larson MG, Levy D, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 2004; 109 (5): 594-600
22. Das SR, Drazner MH, Dries DL, et al. Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study. Circulation 2005; 112 (14): 2163-2168
23. Gilyarov MYu, Novikova N. Biochemical markers in acute coronary syndrome. Kardiologiya i serdechno-sosudistaya khirurgiya 2009: 2 (5); 12-17
24. Jaffe AS, Babuin, Apple FS. Biomarkers in acute cardiac disease: the present and the future. J Am Coll Cardiol 2006; 48: 1-11
25. Omland T, deLemos JA, Morrow DA, et al. Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes. Am J Cardiol 2002; 89: 463-465
26. Lemos JA de, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001; 345:1014-1021
27. Ogawa A, Seino Y, Yamashita T, et al. Difference in elevation of N-terminal pro-BNP and conventional cardiac markers between patients with ST elevation vs non-ST elevation acute coronary syndrome. Circ J 2006; 70: 1372-1378
28. Godkar D, Bachu K, Dave B, et al. B-type natriuretic peptide (BNP) and pro-BNP: role of emerging markers to guide therapy and determine prognosis in cardiovascular disorders. Am J Ther 2008; 15: 150-156
29. Sarullo FM, Gristina T, Brusca, et al. Usefulness of NT-pro-BNP in predicting residual myocardial ischemia in patients with ST elevation acute myocardial infarction. Minerva Cardioangiol 2007; 55: 149-155
30. JernbergT, Stridsberg M, Venge P, Lindahl B. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol 2002; 40 (3): 437-445
31. James SK, Lindahl B, Siegbahn A, et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO) — IVsubstudy. Circulation 2003; 108: 275-281
32. Tapanainen JM, Lindgren KS, Makikallio TH, et al. Natriuretic peptides as predictors of non-sudden and sudden cardiac death after acute myocardial infarction in the b-blocking era. J Am Coll Cardiol 2004; 43: 757-763
33. Sun T, Wang L, Zhang Y Prognostic value of B-type natriuretic peptide in patients with acute coronary syndrome. Arch Med Res 2006; 37: 502-505.
| Attachment | Size |
|---|---|
| 2017_01_041-046.pdf | 291.86 KB |
Русский
English